P-166

Experiences of simultaneous deceased-donor pancreas living-donor kidney transplantation: A solution for reducing waiting time

Y. Kim, J.B. Park, Y.S. Chung, K.B. Song, J.H. Jung, S.C. Kim, D.J. Han
Asan Medical Center, Surgery, Seoul, South Korea

Simultaneous pancreas kidney transplantation (SPK) is a good treatment of option for the patients with diabetic end-stage renal disease. However, because of limitation of organ-shortage, especially kidney graft, patients should wait more than 4~5 years for SPK on list in Korea. Recently, we performed simultaneous deceased-donor pancreas and living-donor kidney transplantation (SPLK) and herein report 7 cases of SPLK in single center. Totally we performed 7 cases of SPLK between September 2009 and June 2010. Median follow-up duration was 3months (range, 1~11 months) The waiting time on list was a median of 1 months.(range, 0~13 months) All the kidney donor was ABO-compatible relation and all the recipients were negative in CDC and T-flow cytometry crossmatch. Median age was 36 years (31~49) in recipients, 22 years (13~33) in pancreas deceased donor and 49 years (28~62 years) in kidney living donor. The relation of kidney donor was mother in 3 patients, brother in 1, sister in 1and husband in 2. Kidney was obtained from living donor by hand-assisted laparoscopic nephrectomy. Cold ischemic time (CIT) of pancreas was a median of 541 minutes (360~624) and CIT of kidney was a median of 84 minutes (28~106). In all the patients the drainage procedures were systemic and bladder drainage. There was no in-hospital mortality and no re-laparotomy for post-operative bleeding including a Jehovah’s Witness, who discharged without any transfusion of RBC or fresh frozen plasma. All the recipients stopped insulin administration within 24 hours post-reperfusion of pancreas. There was no delayed graft function after kidney transplantation and no graft failure of pancreas or kidney during follow-up. SPLK can be a treatment of option for patients with diabetic end-stage renal disease, reducing waiting time on list and overcoming organ shortage.

P-166

Experiences of simultaneous deceased-donor pancreas living-donor kidney transplantation: A solution for reducing waiting time

Y. Kim, J.B. Park, Y.S. Chung, K.B. Song, J.H. Jung, S.C. Kim, D.J. Han
Asan Medical Center, Surgery, Seoul, South Korea

Simultaneous pancreas kidney transplantation (SPK) is a good treatment of option for the patients with diabetic end-stage renal disease. However, because of limitation of organ-shortage, especially kidney graft, patients should wait more than 4~5 years for SPK on list in Korea. Recently, we performed simultaneous deceased-donor pancreas and living-donor kidney transplantation (SPLK) and herein report 7 cases of SPLK in single center. Totally we performed 7 cases of SPLK between September 2009 and June 2010. Median follow-up duration was 3months (range, 1~11 months) The waiting time on list was a median of 1 months.(range, 0~13 months) All the kidney donor was ABO-compatible relation and all the recipients were negative in CDC and T-flow cytometry crossmatch. Median age was 36 years (31~49) in recipients, 22 years (13~33) in pancreas deceased donor and 49 years (28~62 years) in kidney living donor. The relation of kidney donor was mother in 3 patients, brother in 1, sister in 1and husband in 2. Kidney was obtained from living donor by hand-assisted laparoscopic nephrectomy. Cold ischemic time (CIT) of pancreas was a median of 541 minutes (360~624) and CIT of kidney was a median of 84 minutes (28~106). In all the patients the drainage procedures were systemic and bladder drainage. There was no in-hospital mortality and no re-laparotomy for post-operative bleeding including a Jehovah’s Witness, who discharged without any transfusion of RBC or fresh frozen plasma. All the recipients stopped insulin administration within 24 hours post-reperfusion of pancreas. There was no delayed graft function after kidney transplantation and no graft failure of pancreas or kidney during follow-up. SPLK can be a treatment of option for patients with diabetic end-stage renal disease, reducing waiting time on list and overcoming organ shortage.